COVID-19 Patients Recover Faster with Metabolic Activator Treatment, Study Shows
By HospiMedica International staff writers Posted on 29 Jun 2021 |
Illustration
Metabolic activators can reduce recovery time by as many as 3.5 days in patients with mild-to-moderate COVID-19, according to a new study.
Researchers from the Science for Life Laboratory (SciLifeLab) at KTH Royal Institute of Technology (Stockholm, Sweden) also found that treatment with the metabolic activators improved liver health and decreased the levels of inflammation, as shown by inflammatory markers. Their human phase 3 clinical study showed that patients with mild-to-moderate COVID-19 - who were also receiving standard care - experienced a 3.5 day reduction in recovery time when receiving the combination of metabolic activators, nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate. All four activators are aimed at improving mitochondrial function. The results of the study build on findings from phase 2 clinical data.
Through a randomized, placebo controlled, double blind phase three clinical trial, 309 outpatients were randomly assigned on a 3:1 basis to receive the metabolic activators or placebo. Patients received the combined activators or placebo twice a day for 14 days and clinical status was evaluated through daily telephone check-ins.
“Our phase 3 data shows that metabolic activators significantly improve the recovery, liver health, and markers of inflammation of patients with COVID-19,” said the study’s lead author, Adil Mardinoglu, professor at KTH and Kings College and research fellow at SciLifeLab. “Dysfunctional mitochondria have been implicated in worsened progression for COVID-19, and we are pleased to find that the combination of these metabolic activators helps to remedy the stress put on the body of an infected patient.”
Related Links:
KTH Royal Institute of Technology
Researchers from the Science for Life Laboratory (SciLifeLab) at KTH Royal Institute of Technology (Stockholm, Sweden) also found that treatment with the metabolic activators improved liver health and decreased the levels of inflammation, as shown by inflammatory markers. Their human phase 3 clinical study showed that patients with mild-to-moderate COVID-19 - who were also receiving standard care - experienced a 3.5 day reduction in recovery time when receiving the combination of metabolic activators, nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate. All four activators are aimed at improving mitochondrial function. The results of the study build on findings from phase 2 clinical data.
Through a randomized, placebo controlled, double blind phase three clinical trial, 309 outpatients were randomly assigned on a 3:1 basis to receive the metabolic activators or placebo. Patients received the combined activators or placebo twice a day for 14 days and clinical status was evaluated through daily telephone check-ins.
“Our phase 3 data shows that metabolic activators significantly improve the recovery, liver health, and markers of inflammation of patients with COVID-19,” said the study’s lead author, Adil Mardinoglu, professor at KTH and Kings College and research fellow at SciLifeLab. “Dysfunctional mitochondria have been implicated in worsened progression for COVID-19, and we are pleased to find that the combination of these metabolic activators helps to remedy the stress put on the body of an infected patient.”
Related Links:
KTH Royal Institute of Technology
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans